# Biologic and Preclinical Studies of Myeloid Malignancies

> **NIH NIH R50** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $146,069

## Abstract

Abstract
RAS proto-oncogenes are mutated at high frequency in many different malignancies, and developing
targeted inhibitors to reverse the underlying biochemical aberrations caused by oncogenic RAS alleles
represents a central unsolved problem in cancer therapeutics. Activated Ras engages a complex network of
kinase effector cascades of which the Raf/MEK/ERK and phosphoinositide-3-OH kinase (PI3K), Akt,
mammalian Target of Rapamycin (PI3K/Akt/mTOR) pathways are most implicated in cancer initiation and
maintenance. Kevin Shannon, M.D. leads a research group at the University of California, San Francisco
(UCSF) that focuses on using innovative in vivo mouse models of human hematologic malignancies to
investigate the role of specific Ras effector pathways in leukemia initiation and maintenance, to perform
preclinical trials to elucidate mechanisms of drug response and resistance, and to characterize how
selective pressure imposed by different therapeutic agents modulates cancer evolution. In addition to
performing bench research to address these biologic and translational questions, my responsibilities
include: (1) technology development for the group; (2) oversight of the lab's infrastructure and large mouse
colony; (3) insuring that all animal research is conducted in a safe and ethical manner in accordance with
local and national regulatory requirements; and, (4) primary responsibility for training new lab members of
the Shannon lab (including technicians, graduate students, post-doctoral scholars, and
hematology/oncology fellows) as well as members of collaborating groups in research techniques and the
use of specialized equipment. This application for a R50 NCI Research Specialist Award requests salary
support for these ongoing activities to advance the scientific goals of the following NCI-funded research
projects: Translational Investigation of Ras and NF1 in Myeloid Leukemia (R37 CA72614); Response and
Resistance to Inhibitors of Ras Effectors in Blood Cancers (R01 CA180037); Selectively Targeting
Oncogenic NRAS in Cancer (R01 CA193994); Developmental and Hyperactive Ras SPORE (P50
CA196519); and Research Training in Childhood Cancer (T32 CA128583).

## Key facts

- **NIH application ID:** 9994246
- **Project number:** 5R50CA211452-05
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Jasmine Ching Ying Wong
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $146,069
- **Award type:** 5
- **Project period:** 2016-09-15 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9994246

## Citation

> US National Institutes of Health, RePORTER application 9994246, Biologic and Preclinical Studies of Myeloid Malignancies (5R50CA211452-05). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9994246. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*